HCPCS Level II code J3247 denotes the intravenous injection of secukinumab, billed per 1 mg unit. As an HCPCS Level II injectable drug code, J3247 is used in facility and outpatient infusion settings to document dosing and support payment for the biologic agent. Nationally, drug administration codes such as J3247 are important for tracking utilization of high-cost biologics and ensuring proper billing of unit-based drug supplies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how this code is used in claims, payer coverage considerations, unit-based billing implications, and typical sites of service where intravenous secukinumab is administered. The publication also outlines relevant benchmarks and policy considerations affecting injectable biologics billing, clinical context for IV administration, and common modifiers and billing practices (where available). Data not available in the input is noted where applicable.

This summary provides clinicians, billing professionals, and policy analysts a concise reference on HCPCS Level II code J3247, its clinical use for IV secukinumab administration, and the payer landscape affecting reimbursement and utilization tracking.